~~<i id='2E0AC10D57'><strike id='2E0AC10D57'><tt id='2E0AC10D57'><pre id='2E0AC10D57'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：leisure time 2025-09-28 10:08:56 Page View：446

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ProMED sees offers of support, but its future remains unclear
Next article： Medicare proposal to cover medical devices draws a mixed reaction

focus

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

SNAP should offer more nutrition education

StaffandvolunteersattheHungryMonkfoodpantryprepareanddistributefruitandvegetablestolocalresidentsatt

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Hilary may become 1st tropical storm to make landfall in California in 84 years

1:28AsatelliteimageshowsTropicalStormHilarynearthePacificcoastofMexico,Aug.17,2023.NOAAHurricaneHila